Skip to main content
Search
Search
Advanced Search
Skip main navigation
Free access
Research Article
6 January 2020

Cost–effectiveness analysis of intravitreal aflibercept in the treatment of diabetic macular edema in China

Authors: Jian Ming https://orcid.org/0000-0002-4987-6391, Yabing Zhang, Xun Xu, Mingwei Zhao, Yusheng Wang, Youxin Chen, Feng Zhang, Jiawei Wang, Jun Liu, Xinran Zhao, Rong Han, and Shanlian Hu [email protected]Author Info & Affiliations
Volume 9, Number 3
https://doi.org/10.2217/cer-2019-0174
PDFFormats

Abstract

Aim: To evaluate the cost–effectiveness of intravitreal aflibercept compared with macular laser photocoagulation and ranibizumab for diabetic macular edema (DME) in China. Methods: A Markov model was developed to reflect the vision changes in DME patients. Parameters were estimated from VIVID-EAST trial data, published literature and physician surveys. Results: In a 20-year horizon, intravitreal aflibercept was associated with 7.825 quality-adjusted life years (QALYs) and 217,841 Chinese Yuan Renminbi (CNY), laser photocoagulation was associated with 7.189 QALYs and 135,489 CNY, and ranibizumab was associated with 7.462 QALYs and 222,477 CNY. The incremental cost–effectiveness ratios were 129,397 CNY/QALY and -12,774 CNY/QALY for intravitreal aflibercept versus laser photocoagulation and ranibizumab, respectively. Conclusion: Intravitreal aflibercept was considered as a cost-effective strategy for DME when compared with laser photocoagulation; it was considered as a dominant strategy when compared with ranibizumab.

Supplementary Material

File (suppl_data.zip)

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Yau JW, Rogers SL, Kawasaki R et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3), 556–564 (2012).
PubMed
Google Scholar
2.
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 376(9735), 124–136 (2010).
PubMed
Google Scholar
3.
Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 26(9), 2653–2664 (2003).
PubMed
Google Scholar
4.
Lim LS, Liew G, Cheung N, Mitchell P, Wong TY. Mixed messages on systemic therapies for diabetic retinopathy. Lancet 376(9751), 1461; author reply 1462 (2010).
PubMed
Google Scholar
5.
Cheung GC, Yoon YH, Chen LJ et al. Diabetic macular oedema: evidence-based treatment recommendations for Asian countries. Clin. Exp. Ophthalmol. 46(1), 75–86 (2018).
PubMed
Google Scholar
6.
Williams R, Airey M, Baxter H et al. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 18(10), 963 (2004).
PubMed
Google Scholar
7.
Wang L, Gao P, Zhang M et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 317(24), 2515–2523 (2017).
PubMed
Google Scholar
8.
Liu Y, Song Y, Tao L et al. Prevalence of diabetic retinopathy among 13473 patients with diabetes mellitus in China: a cross-sectional epidemiological survey in six provinces. BMJ Open 7(1), e013199 (2017).
PubMed
Google Scholar
9.
Gangnon RE, Davis MD, Hubbard LD et al. A severity scale for diabetic macular edema developed from ETDRS data. Invest. Ophthalmol. Vis. Sci. 49(11), 5041–5047 (2008).
PubMed
Google Scholar
10.
Lamoureux EL, Tai ES, Thumboo J et al. Impact of diabetic retinopathy on vision-specific function. Ophthalmology 117(4), 757–765 (2010).
PubMed
Google Scholar
11.
Shea AM, Curtis LH, Hammill BG et al. Resource use and costs associated with diabetic macular edema in elderly persons. Arch. Ophthalmol. 126(12), 1748–1754 (2008).
PubMed
Google Scholar
12.
Group ETDRSR. Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report no. 4. Int. Ophthalmol. Clinics 27(4), 265–272 (1987).
PubMed
Google Scholar
13.
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 237(4), 185–222 (2017).
PubMed
Google Scholar
14.
Solomon SD, Chew E, Duh EJ et al. Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes Care 40(3), 412–418 (2017).
PubMed
Google Scholar
15.
Ophthalmology ICO. Updated 2017 ICO Guidelines for Diabetic Eye Care (2016). http://www.icoph.org/enhancing_eyecare/diabetic_eyecare.html
Google Scholar
16.
De Oliveira Dias JR, Andrade GC, Novais EA, Farah ME, Rodrigues EB. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. Int. J. Retina Vitreous 2(1), 3 (2016).
PubMed
Google Scholar
17.
Korobelnik JF, Do DV, Schmidt-Erfurth U et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121(11), 2247–2254 (2014).
PubMed
Google Scholar
18.
Chen Y. Intravitreal aflibercept is effecttive in the treatment of patients with diabetic macular edema from asia and russia: results from the VIVID-EAST Study. Presented at: The 9th Congress of Asia Pacific Vitreo-retina Society. Sydney, Australia, 31 July–2 August 2015.
Google Scholar
•• This head-to-head Phase III clinical trial study provided important comparative effectiveness data of intravitreal aflibercept versus laser in the treatment of diabetic macular edema in China.
19.
National Bureau of Statistics of China. China Statistical Yearbook-2017. China Statistics Press (2017). http://www.stats.gov.cn/tjsj/ndsj/2017/indexeh.htm
Google Scholar
20.
Liu GB. China guidelines for pharmacoeconomic evaluations and manual (2015).
Google Scholar
21.
Pershing S, Enns EA, Matesic B, Owens DK, Goldhaber-Fiebert JD. Cost-effectiveness of treatment of diabetic macular edema. Ann. Intern. Med. 160(1), 18–29 (2014).
PubMed
Google Scholar
22.
Klein R, Klein BE, Moss SE, Davis MD, Demets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch. Ophthalmol. 102(4), 527–532 (1984).
PubMed
Google Scholar
23.
Christ SL, Lee DJ, Lam BL, Zheng DD, Arheart KL. Assessment of the effect of visual impairment on mortality through multiple health pathways: structural equation modeling. Invest. Ophthalmol. Vis. Sci. 49(8), 3318–3323 (2008).
PubMed
Google Scholar
24.
Jin Peiyao, Peng Jinjuan, Zou Haidong et al. A 5-year prospective study of type 2 diabetes patients in Shanghai Xinjing Community 1. The incidence and risk factors of diabetic retinopathy and diabetic macular edema in Chinese type 2 diabetes residents. Chin. J. Exp. Ophthalmol. 34(4), 363–367 (2016).
Google Scholar
25.
Xu Xun, Zheng Ying. Focusing on the treatment of diabetic macular edema. Chin. J. Ocul. Fundus Dis. 32(2), 119–121 (2016).
Google Scholar
26.
Jackson CH. Multi-state models for panel data: the msm package for R. J. Stat. Software 38(8), 1–29 (2011).
Google Scholar
• Provided the R code to derive the transition probabilities of intravitreal aflibercept and laser treatment from individual patient-level data.
27.
Korobelnik JF, Kleijnen J, Lang SH et al. Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME). BMC Ophthalmol. 15, 52 (2015).
PubMed
Google Scholar
•• The transition probabilities for ranibizumab (a main comparator in this study) were calculated based on the mean log odds ratios compared with intravitreal aflibercept using results from this network-meta analysis.
28.
Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118(4), 615–625 (2011).
PubMed
Google Scholar
29.
Ohji M, Ishibashi Sr T, Group RS. Efficacy and safety of ranibizumab 0.5 mg as monotherapy or adjunctive to laser versus laser monotherapy in Asian patients with visual impairment due to diabetic macular edema: 12-month results of the REVEAL study. Invest. Ophthalmol. Visual Sci. 53(14), 4664–4664 (2012).
Google Scholar
30.
China Disabled Persons’ Federatopm. China’s practical assessment standards for disabled people (2006). http://www.gov.cn/ztzl/gacjr/content_459939.htm
Google Scholar
31.
National Bureau of Statistics of China. Consumer Price Index (2018). http://data.stats.gov.cn/english/easyquery.htm?cn=A01
Google Scholar
32.
Shanghai Disabled Persons’ Federation. Measures for the administration of living subsidies for difficult persons with disabilities and nursing subsidy for severely disabled persons (2016). http://www.shanghai.gov.cn/nw2/nw2314/nw2319/nw12344/u26aw46410.html
Google Scholar
33.
Czoski-Murray C, Carlton J, Brazier J, Young T, Papo NL, Kang HK. Valuing condition-specific health states using simulation contact lenses. Value Health 12(5), 793–799 (2009).
PubMed
Google Scholar
•• Provided utilities based on the two-eye model and is accepted by NICE.
34.
Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology 114(6), 1170–1178 (2007).
PubMed
Google Scholar
35.
Brändle M, Azoulay M, Greiner R. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. Int. J. Clin. Pharmacol. Ther. 45(4), 203–220 (2007).
PubMed
Google Scholar
36.
Pershing S, Enns EA, Matesic B, Owens DK, Goldhaber-Fiebert JD. Cost-effectiveness of treatment of diabetic macular edema. Ann. Intern. Med. 160(1), 18–29 (2014).
PubMed
Google Scholar
37.
Sorensen SV, Kansal AR, Connolly S et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thrombosis Haemostasis 105(05), 908–919 (2011).
PubMed
Google Scholar
38.
Li H, Liu GG, Wu J, Wu J-H, Dong C-H, Hu S-L. Recent pricing negotiations on innovative medicines pilot in China: experiences, implications, and suggestions. Value Health Reg. Issues 15, 133–137 (2018).
PubMed
Google Scholar
39.
Muston D, Korobelnik JF, Reason T et al. An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data. BMC Ophthalmol. 18(1), 340 (2018).
PubMed
Google Scholar
40.
Régnier S, Malcolm W, Allen F, Wright J, Bezlyak V. Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis. PLoS ONE 9(7), e102309 (2014).
PubMed
Google Scholar
41.
Régnier SA, Malcolm W, Haig J, Xue W. Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective. Clinicoecon. Outcomes Res. 7, 235 (2015).
PubMed
Google Scholar
42.
Kourlaba G, Relakis J, Mahon R et al. Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema. Cost Eff. Resour. Alloc. 14(1), 7 (2016).
PubMed
Google Scholar
43.
Priaulx J, Napier J, Barzey V, Lovato E. The cost effectiveness of aflibercept compared to ranibizumab and laser in the management of diabetic macular oedema (DMO). Presented at: The Royal College of Ophthalmologists Annual Congress 2015. London, UK, 17 March 2015.
Google Scholar
44.
Do DV, Nguyen QD, Boyer D et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 119(8), 1658–1665 (2012).
PubMed
Google Scholar
45.
Zhang Yabing, Hu Shanlian, Chang Jinghua. Analysis on the disease burden of wet age-related macular degeneration in China. Chin. Health Econ. 34(1), 63–65 (2015).
Google Scholar
|